Pathos AI strikes deals with Bristol Myers Squibb and Tempus AI

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. FIX
9. TSCO
10. BE

Go back to Pathos AI strikes deals with Bristol Myers Squibb and Tempus AI

Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer’s Disease and Other Neurological Conditions

October 23, 2026 9:00 AM EDT

Tempus to build a de-identified dataset from hundreds of thousands of patients with neurological conditions; Pathos to license the dataset under a five-year, $55 million agreement Pathoss AI expertise and agentic AI platform, Foundry, combined with Bristol Myers Squibbs (BMS) neuroscience drug development expertise to be applied to understanding disease progression and advancing new therapies BMS leads Pathoss Series E financing and gains non-exclusive strategic access to Pathoss AI platform, Pathos Foundry, across its broader portfolio, along with three-year exclusive rights to support its neuroscience development... More